A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Citation record

Study start

2026-01-02

NCT number

NCT07063745

Phase

Phase2, Phase3

Overall status

Recruiting

Study type

Interventional

Lead sponsor

Bristol-Myers Squibb

Enrollment

590 participants

Conditions

Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Interventions

BMS-986504 (Drug) · Pembrolizumab (Drug) · Placebo (Other) · Cisplatin (Drug) · Carboplatin (Drug) · Pemetrexed (Drug)

Last updated at source

23 Oct 2026

Original source

https://clinicaltrials.gov/study/NCT07063745

This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.